Home Cart Sign in  
Chemical Structure| 1619931-27-9 Chemical Structure| 1619931-27-9

Structure of Seralutinib
CAS No.: 1619931-27-9

Chemical Structure| 1619931-27-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Seralutinib is a potent and novel inhaled PDGFR inhibitor, used in the study for pulmonary arterial hypertension.

Synonyms: GB002; PK10571

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Seralutinib

CAS No. :1619931-27-9
Formula : C27H27N5O3
M.W : 469.54
SMILES Code : O=C(C1=CC(C)=CN=C1)NC2=CC=CC([C@@H](NC3=NC(C4=CC=C(OC)C(OC)=C4)=CN=C3)C)=C2
Synonyms :
GB002; PK10571
MDL No. :MFCD28502207
InChI Key :JHJNPOSPVGRIAN-SFHVURJKSA-N
Pubchem ID :91663352

Safety of Seralutinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Seralutinib

RTK

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats SU5416/Hypoxia (SU5416/H) and monocrotaline pneumonectomy (MCTPN) models Inhaled 2.5 mg/kg and 4.6 mg/kg, twice daily Twice daily for 2 weeks Seralutinib improved cardiopulmonary haemodynamic parameters and reduced small pulmonary artery muscularisation and right ventricle hypertrophy in both models. In the SU5416/H model, seralutinib improved cardiopulmonary haemodynamic parameters, restored lung BMPR2 protein levels and decreased N-terminal pro-brain natriuretic peptide (NT-proBNP), more than imatinib. Eur Respir J. 2022 Dec 1;60(6):2102356
Rats SU5416/Hypoxia (SU5416/H) and monocrotaline pneumonectomy (MCTPN) models Inhaled 2.5 mg/kg,4.6 mg/kg Twice daily for 2 weeks Evaluated the efficacy of seralutinib in PAH models, showing improved cardiopulmonary hemodynamic parameters, reduced small pulmonary artery muscularization, and right ventricular hypertrophy Eur Respir J. 2022 Dec 1;60(6):2102356

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.13mL

0.43mL

0.21mL

10.65mL

2.13mL

1.06mL

21.30mL

4.26mL

2.13mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories